Last reviewed · How we verify
HTL0009936
At a glance
| Generic name | HTL0009936 |
|---|---|
| Also known as | 9936, HTL0009936, Placebo |
| Sponsor | Nxera Pharma UK Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment (PHASE1)
- Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects (PHASE1)
- Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HTL0009936 CI brief — competitive landscape report
- HTL0009936 updates RSS · CI watch RSS
- Nxera Pharma UK Limited portfolio CI